Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
MESNA (UNII: NR7O1405Q9) (2-MERCAPTOETHANESULFONIC ACID - UNII:VHD28S0H7F)
Baxter Healthcare Corporation
MESNA
MESNA 100 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see Warnings and Precautions (5.1)] . Risk Summary Mesna is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm when administered to a pregnant woman. Refer to the ifosfamide prescribing information for more information on use during pregnancy. Mesna injection contains the preservative benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4)]. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies
Mesna injection 100 mg/mL If mesna is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions. MESNEX (mesna) tablets
New Drug Application
MESNA- MESNA INJECTION, SOLUTION BAXTER HEALTHCARE CORPORATION ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MESNA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MESNA. MESNEX (MESNA) TABLETS, FOR ORAL USE MESNA INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1988 RECENT MAJOR CHANGES Warnings and Precautions, Benzyl Alcohol Toxicity (5.3) 12/2018 INDICATIONS AND USAGE Mesna is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1) DOSAGE AND ADMINISTRATION Mesna may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is adjusted, the ratio of mesna to ifosfamide should be maintained. (2) Intravenous Dosing Schedule: 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m -- -- Mesna injection 240 mg/m 240 mg/m 240 mg/m Intravenous and Oral Dosing Schedule: 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m -- -- Mesna injection 240 mg/m -- -- MESNEX tablets -- 480 mg/m 480 mg/m Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. (2.3) DOSAGE FORMS AND STRENGTHS • • CONTRAINDICATIONS Known hypersensitivity to mesna or to any of the excipients in mesna, including benzyl alcohol. (4) WARNINGS AND PRECAUTIONS • • • • ADVERSE REACTIONS The most common adverse reactions (> 10%) when mesna is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence. (6.1) To report S Lees het volledige document